Cancer continues to represent a growing global health challenge in 2026, with incidence rising sharply across both developed and emerging markets. India reflects this trend, now recording approximately 1.56 million new cases annually and ranking among the top three countries worldwide for cancer burden. With projections pointing toward a significant long term increase in cases driven by aging populations and lifestyle factors, demand for high quality care is accelerating, placing cancer hospitals in India at the centre of both domestic and international healthcare conversations.
In response, India has strengthened its oncology ecosystem, with cancer hospitals in India playing an increasingly coordinated role through national frameworks such as the National Cancer Grid. Bringing together more than 300 centres, the network supports clinical collaboration, research, and standardised treatment protocols, helping address a large proportion of the country’s cancer burden. However, 2026 trends also highlight ongoing challenges, particularly late stage diagnosis and uneven access to screening, reinforcing the need for continued investment in early detection and capacity building.
For international patients, cancer hospitals in India remain an attractive option, combining advanced treatment capabilities with cost efficiency. India is seeing sustained interest from overseas patients seeking oncology care, particularly in complex areas such as radiation therapy. The country’s investment in high end infrastructure, including proton therapy centres and expanding genomic capabilities, positions leading cancer hospitals in India as competitive players on the global stage, even as affordability and access remain key differentiators.
Several national and international surveys in India and the United States regularly rank hospitals based on their oncology expertise, clinical outcomes, and patient satisfaction. Drawing on these global surveys, along with insights from our global medical advisory network, Medical Travel Market has identified five leading cancer hospitals in India. These hospitals in India stand out for their commitment to excellence in cancer care, advanced technology, multidisciplinary expertise, and the value they deliver to patients seeking high-quality cancer treatment in India.
Max Super Speciality Hospital – Saket, New Delhi
Max Super Speciality Hospital (MSSH) anchors Max Healthcare’s oncology program across Delhi. The hospital features multi-disciplinary cancer care (surgical, medical, radiation oncology) and is consistently recognized among India’s leading hospitals; Newsweek’s 2025 list places MSSH Saket among the country’s top hospitals.
Beyond clinical services, Max Institute of Cancer Care hosts “Max Onco Updates,” a scientific forum convening >1,000 experts to advance teaching, research and clinical collaboration – an indicator of the group’s academic footprint alongside patient care.
Apollo Hospitals – Chennai (Apollo Proton Cancer Centre)
Apollo’s Chennai campus is home to the Apollo Proton Cancer Centre (APCC), South Asia’s first clinical proton-therapy facility (inaugurated January 2019). APCC brought precision particle therapy to the region for complex tumors near critical structures (e.g., skull base, pediatrics), expanding India’s radiotherapy services for international patients.
The broader Apollo network also reports innovations across transplant and day-care oncology pathways, underlining a push toward faster recovery and lower inpatient burden where appropriate.
Medanta – The Medicity, Gurugram
Medanta’s Cancer Institute delivers comprehensive oncology with strong surgical and radiation programs (CyberKnife, TomoTherapy). The Gurugram campus has been repeatedly cited by Newsweek among India’s best private hospitals, reflecting peer and outcomes-based recognition.
In radiation oncology quality assurance, Medanta reports achieving an internationally benchmarked Postal Dosimetry Audit for CyberKnife/TomoTherapy, signaling rigorous dose-delivery accuracy, a key determinant of safe, effective therapy. The group also highlights ongoing work in precision oncology and AI-enabled pathways.
All India Institute of Medical Sciences (AIIMS) – New Delhi
AIIMS houses the Dr. B.R.A. Institute Rotary Cancer Hospital, one of India’s major public academic cancer centers with a long-running hematopoietic stem-cell transplant program. AIIMS’ oncology services pair high clinical volumes with education and research outputs typical of a national referral hub.
The National Cancer Institute at Jhajjar – an AIIMS extension – adds 700+ dedicated cancer beds, multiple PET scanners, a high-capacity OT complex and, notably, India’s first public-sector proton therapy service. This significantly expands access to advanced modalities within the public system.
Indraprastha Apollo Hospitals – New Delhi
Indraprastha Apollo is one of India’s most established private tertiary centers and was the first hospital in India to receive Joint Commission International (JCI) accreditation in 2005 – a marker of adherence to rigorous international quality and safety standards.
Oncology at Apollo Delhi spans comprehensive solid-tumor and hematology services, including a dedicated Bone Marrow Transplant & Cellular Therapy center that the hospital has continued to expand – part of a networked oncology service line that integrates surgical robotics, advanced imaging and supportive care.
Helping Patients Find Treatment in India
If you are interested in cancer treatment in India and would like to obtain a cost estimate or second opinion, our medical travel team is here to help. Get in touch below to begin your healthcare journey.
